The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
Open accessAbstract
Key Points: The bispecific, tetravalent antibody AFM13 represents a new approach engaging natural killer cells via CD16A to fight CD30+ malignancies. AFM13 is well tolerated and active in Hodgkin lymphoma patients who received all standard therapies, including brentuximab vedotin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Self-citationBrentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
Topp, M. S., Gökbuget, N., Stein, A. S., Zugmaier, G., O'Brien, S., Bargou, R. C., Dombret, H., Fielding, A. K., Heffner, L., Larson, R. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71170-2 · Cited by 1,269
Self-citationTopp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
Self-citationDiehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dörken, B., Müller-Hermelink, H.-K., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022473 · Cited by 838
Improved Endpoints for Cancer Immunotherapy Trials
Hoos, A., Eggermont, A. M. M., Janetzki, S., Hodi, F. S., Ibrahim, R., Anderson, A., Humphrey, R., Blumenstein, B., Old, L., & Wolchok, J. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq310 · Cited by 518
High Expression of the CC Chemokine TARC in Reed-Sternberg Cells
van den Berg, A., Visser, L., & Poppema, S. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65424-7 · Cited by 367
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
Fehniger, T. A., Larson, S., Trinkaus, K., Siegel, M. J., Cashen, A. F., Blum, K. A., Fenske, T. S., Hurd, D. D., Goy, A., Schneider, S. E., et al. (2011) · Blood · doi:10.1182/blood-2011-07-362475 · Cited by 191
Cited by
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Vivier, E., Rebuffet, L., Narni-Mancinelli, E., Cornen, S., Igarashi, R. Y., & Fantin, V. R. (2024) · Nature · doi:10.1038/s41586-023-06945-1 · Cited by 467
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Gauthier, L., Morel, A., Anceriz, N., Rossi, B., Blanchard-Alvarez, A., Grondin, G., Trichard, S., Cesari, C., Sapet, M., Bosco, F., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.041 · Cited by 439
Metadata
- Authors
- Rothe, A., Sasse, S., Topp, M. S., Eichenauer, D. A., Hummel, H., Reiners, K. S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., Ravic, M., Knackmuss, S., Marschner, J.-P., Pogge von Strandmann, E., Borchmann, P., & Engert, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2015-06-25
- Volume
- 125
- Issue
- 26
- Pages
- 4024-4031
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2123023182
- Cited by
- 337
- References
- 29
- FWCI
- 19.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. https://app.cochat.ai/papers/10.1182/blood-2014-12-614636
- The paper
- Rothe, A., Sasse, S., Topp, M. S., Eichenauer, D. A., Hummel, H., Reiners, K. S., Dietlein, M., Kuhnert, G., Kessler, J., Buerkle, C., Ravic, M., Knackmuss, S., Marschner, J.-P., Pogge von Strandmann, E., Borchmann, P., & Engert, A. (2015). A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. https://doi.org/10.1182/blood-2014-12-614636
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.